reduced-intensity transplant conditioning procedure

OTHER3 trials

Sponsors

University of Nebraska, Alliance for Clinical Trials in Oncology, OHSU Knight Cancer Institute

Conditions

Acute Myeloid LeukemiaChronic Myeloproliferative DisordersLeukemiaLymphomaLymphoproliferative DisorderMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasms

Phase 1

Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer

WithdrawnNCT00816413

University of NebraskaChronic Myeloproliferative Disorders, Leukemia, Lymphoma +2

Start: 2008-09-30End: 2010-02-28Updated: 2023-08-14

Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation

Not yet recruitingNCT07548983

OHSU Knight Cancer InstituteAcute Myeloid Leukemia

Start: 2026-05-20End: 2028-12-29Target: 40Updated: 2026-04-23

Phase 2

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant

TerminatedNCT01118013

Alliance for Clinical Trials in OncologyLeukemia, Lymphoma, Lymphoproliferative Disorder +3

Start: 2010-12-31End: 2013-08-31Updated: 2017-03-24